Mechanisms of Disease: erythropoietin resistance in patients with both heart and kidney failure (Q37038424)

17 August 2017

1 reference

title

Mechanisms of Disease: erythropoietin resistance in patients with both heart and kidney failure (English)

1 reference

17 August 2017

0 references

1 reference

Karien van der Putten

1

1 reference

17 August 2017

Branko Braam

2

1 reference

17 August 2017

Kim E Jie

3

1 reference

17 August 2017

Carlo A J M Gaillard

4

1 reference

17 August 2017

1 January 2008

1 reference

Nature Clinical Practice Nephrology

17 August 2017

1 reference

17 August 2017

4

1 reference

17 August 2017

1

1 reference

17 August 2017

47-57

1 reference

https://scigraph.springernature.com/pub.10.1038/ncpneph0655

17 August 2017

0 references

cites work

How to get the best out of r-HuEPO.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0655

Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0655

Erythropoietin resistance: the role of inflammation and pro-inflammatory cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0655

The severe cardiorenal syndrome: 'Guyton revisited'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0655

7 January 2021

Erythropoietin and the cardiorenal syndrome: cellular mechanisms on the cardiorenal connectors

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0655

7 January 2021

Interpretation of erythropoietin levels in patients with various degrees of renal insufficiency and anemia

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0655

7 January 2021

Anemia of chronic disease.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0655

7 January 2021

Role of secondary hyperparathyroidism in erythropoietin resistance of chronic renal failure patients.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0655

7 January 2021

Anemia, Renal Dysfunction, and Their Interaction in Patients With Chronic Heart Failure

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0655

7 January 2021

The role of ACE inhibitors and angiotensin II receptor blockers in the response to epoetin

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0655

7 January 2021

Anemia Is Common in Heart Failure and Is Associated With Poor Outcomes

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0655

7 January 2021

Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0655

7 January 2021

Angiotensin II stimulates proliferation of normal early erythroid progenitors

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0655

7 January 2021

Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0655

7 January 2021

Levels of hematopoiesis inhibitor N-acetyl-seryl-aspartyl-lysyl-proline partially explain the occurrence of anemia in heart failure

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0655

7 January 2021

High dose enalapril impairs the response to erythropoietin treatment in haemodialysis patients.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0655

7 January 2021

The impact of withdrawing ACE inhibitors on erythropoietin responsiveness and left ventricular hypertrophy in haemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0655

7 January 2021

Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0655

7 January 2021

Hemodilution is common in patients with advanced heart failure

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0655

7 January 2021

Left ventricular mass index increase in early renal disease: Impact of decline in hemoglobin

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0655

7 January 2021

The impact of anemia on cardiomyopathy, morbidity, and and mortality in end-stage renal disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0655

7 January 2021

Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0655

7 January 2021

Anemia treatment in the pre-ESRD period and associated mortality in elderly patients.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0655

7 January 2021

Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS).

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0655

7 January 2021

Associations between Changes in Hemoglobin and Administered Erythropoiesis-Stimulating Agent and Survival in Hemodialysis Patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0655

7 January 2021

Impact of epoetin alfa on clinical end points in patients with chronic renal failure: a meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0655

7 January 2021

Changes in left ventricular size, wall thickness, and function in anemic patients treated with recombinant human erythropoietin

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0655

7 January 2021

Effect of erythropoietin on cardiovascular prognosis parameters in hemodialysis patients.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0655

7 January 2021

The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0655

7 January 2021

Normalization of hemoglobin level in patients with chronic kidney disease and anemia

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0655

7 January 2021

Correction of anemia with epoetin alfa in chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0655

7 January 2021

Anemia and its relationship to clinical outcome in heart failure.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0655

7 January 2021

Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: the Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0655

7 January 2021

Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0655

7 January 2021

The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0655

7 January 2021

Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0655

7 January 2021

Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0655

7 January 2021

Erythropoietin production by interstitial cells of hypoxic monkey kidneys

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0655

7 January 2021

Differentiating the functional role of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha (EPAS-1) by the use of RNA interference: erythropoietin is a HIF-2alpha target gene in Hep3B and Kelly cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0655

7 January 2021

HIF-2alpha regulates murine hematopoietic development in an erythropoietin-dependent manner

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0655

7 January 2021

Inhibition of erythropoietin gene expression signaling involves the transcription factors GATA-2 and NF-kappaB.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0655

7 January 2021

Sox6 cell-autonomously stimulates erythroid cell survival, proliferation, and terminal maturation and is thereby an important enhancer of definitive erythropoiesis during mouse development

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0655

7 January 2021

Erythropoietin receptor mRNA expression in human endothelial cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0655

7 January 2021

Hematopoietic factor erythropoietin fosters neuroprotection through novel signal transduction cascades

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0655

7 January 2021

Epoetin alfa. Clinical evolution of a pleiotropic cytokine

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0655

7 January 2021

Erythropoietin regulates endothelial progenitor cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0655

7 January 2021

Endothelial progenitor cell proliferation and differentiation is regulated by erythropoietin Rapid Communication

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0655

7 January 2021

Erythropoietin promotes endothelial progenitor cell proliferative and adhesive properties in a PI 3-kinase-dependent manner

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0655

7 January 2021

Erythropoietin and hypoxia stimulate erythropoietin receptor and nitric oxide production by endothelial cells.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0655

7 January 2021

A novel protective effect of erythropoietin in the infarcted heart

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0655

7 January 2021

Erythropoietin protects against ischaemic acute renal injury

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0655

7 January 2021

Development of a new radioimmunoassay for erythropoietin using recombinant erythropoietin

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0655

7 January 2021

Blood levels of erythropoietin in congestive heart failure and correlation with clinical, hemodynamic, and hormonal profiles

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0655

7 January 2021

Elevated level of erythropoietin in congestive heart failure relationship to renal perfusion and plasma renin

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0655

7 January 2021

Circulating erythropoietin levels and prognosis in patients with congestive heart failure: comparison with neurohormonal and inflammatory markers

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0655

7 January 2021

Prognostic value of plasma erythropoietin on mortality in patients with chronic heart failure

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0655

7 January 2021

Inflammatory and atherosclerotic interactions in the depleted uremic patient.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0655

7 January 2021

What are the causes and consequences of the chronic inflammatory state in chronic dialysis patients?

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0655

7 January 2021

Elevated circulating levels of tumor necrosis factor in severe chronic heart failure

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0655

7 January 2021

Tumour necrosis factor alpha in severe congestive cardiac failure

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0655

7 January 2021

Proinflammatory cytokines lowering erythropoietin production

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0655

7 January 2021

Nitric oxide suppression of human hematopoiesis in vitro. Contribution to inhibitory action of interferon-gamma and tumor necrosis factor-alpha

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0655

7 January 2021

The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0655

7 January 2021

Crystal structure of the ectodomain of human transferrin receptor

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0655

7 January 2021

IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0655

7 January 2021

Regulation of transepithelial transport of iron by hepcidin.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0655

7 January 2021

Hepcidin inhibits in vitro erythroid colony formation at reduced erythropoietin concentrations

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0655

7 January 2021

Is hepcidin a link between anemia, inflammation and liver function in hemodialyzed patients?

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0655

7 January 2021

Does hepcidin affect erythropoiesis in hemodialysis patients?

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0655

7 January 2021

Dimerization of the extracellular domain of the erythropoietin (EPO) receptor by EPO: one high-affinity and one low-affinity interaction

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0655

7 January 2021

Ligand-independent oligomerization of cell-surface erythropoietin receptor is mediated by the transmembrane domain

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0655

7 January 2021

Erythropoietin receptors: their role beyond erythropoiesis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0655

7 January 2021

Activation of erythropoietin receptor in the absence of hormone by a peptide that binds to a domain different from the hormone binding site

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0655

7 January 2021

Small peptides as potent mimetics of the protein hormone erythropoietin

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0655

7 January 2021

Functional mimicry of a protein hormone by a peptide agonist: the EPO receptor complex at 2.8 A

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0655

7 January 2021

CIS3/SOCS-3 suppresses erythropoietin (EPO) signaling by binding the EPO receptor and JAK2

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0655

7 January 2021

Endocytosis of growth factor receptors

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0655

7 January 2021

Both proteasomes and lysosomes degrade the activated erythropoietin receptor

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0655

7 January 2021

JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0655

7 January 2021

Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0655

7 January 2021

The critical role of SRC homology domain 2-containing tyrosine phosphatase-1 in recombinant human erythropoietin hyporesponsive anemia in chronic hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0655

7 January 2021

Pim-1 kinase inhibits STAT5-dependent transcription via its interactions with SOCS1 and SOCS3.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0655

7 January 2021

Neocytolysis on descent from altitude: a newly recognized mechanism for the control of red cell mass

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0655

7 January 2021

Erythropoietin withdrawal leads to the destruction of young red cells at the endothelial-macrophage interface

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0655

7 January 2021

Neocytolysis contributes to the anemia of renal disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0655

7 January 2021

Identifiers

DOI

10.1038/NCPNEPH0655

1 reference

Dimensions Publication ID

17 August 2017

0 references

1 reference